JinMatrix Obtains US Patent for Multiplex Molecular Diagnostic Core Technology
[Asia Economy Reporter Moon Hyewon] JinMatrix announced on the 8th that it has obtained a US patent for its proprietary multiplex molecular diagnostic core technology, ‘C-Tag’.
The patented technology is a platform used in the Neoplex multiplex molecular diagnostic product line. The company explained that it is recognized as a next-generation core technology capable of advanced multiplexing, surpassing the previously known limit of up to five simultaneous analyses in conventional real-time PCR technology.
Hot Picks Today
"Even Hard-Earned Money Can't Buy It"…Hanwoo Beef Sales Drop Sharply After Three Years
- "Don't Say 'Americano' Anymore" After the Uproar... Now a Surge in 'Patriotic Spending' Sweeps Canada
- [Exclusive] Former Edison Motors Chairman Youngkwon Kang Acquitted of '10 Billion Won Loan and Investment Fraud' Charges [Invest&Law]
- "114-Year-Old Mother Who Loves Bread Porridge; Eldest Daughter Is 94"… Japan’s Centenarian Population Surpasses 100,000
- 'Pronounced Dead,' Now Boiling Again... Chinese Millennials and Gen Z Seek 'Premium Ramen'
JinMatrix is currently preparing a comprehensive respiratory virus panel rapid diagnostic product applying the C-Tag core technology to its COVID-19 diagnostic products, which are being exported to Europe, the Middle East, and other regions.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
